Author

J. Custers

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 4 Organism:mouse· 3 Research Focus:drug response / drug discovery· 2 Research Focus:cell type annotation· 1 Assay:DNA methylation· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1

Frequent Co-Authors

H. Schuitemaker· 4 shared F. Wegmann· 3 shared L. Muchene· 3 shared R. Bos· 3 shared A. H. de Wilde· 2 shared D. H. Barouch· 2 shared D. Zuijdgeest· 2 shared E. J. Snijder· 2 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

H. Schuitemaker

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Immunogenicity of an Ad26-based SARS-CoV-2 Omicron Vaccine in Naïve Mice and SARS-CoV-2 Spike Pre-immune Hamsters

M. Swart, A. de Wilde, S. Schmit-Tillemans, J. Verspuij, C. Daal, Y. Choi, A. Perkasa, E. Kourkouta, I. Tahiri, M. Mulders, A. I. Gil, L. Muchene, J. Juraszek, J. Vellinga, J. Custers, , R. Zahn

This study evaluates an Ad26-based Omicron spike vaccine in mice and pre-immune hamsters, showing it induces neutralizing antibodies against Omicron and Delta variants.

bioRxiv · Mar 4, 2022 · PreprintImmunology

Ad26.COV2.S elicited neutralizing activity against Delta and other SARS-CoV-2 variants of concern

M. Jongeneelen, K. Kaszas, D. Veldman, J. Huizingh, R. van der Vlugt, T. Schouten, D. Zuijdgeest, T. Uil, G. van Roey, N. Guimera, M. Navis, R. Bos, M. Le Gars, J. Sadoff, L. Muchene, , B. Brandenburg

This study evaluates the neutralizing activity of Ad26.COV2.S vaccine sera against SARS-CoV-2 variants, finding reduced effectiveness against Beta and Gamma but less reduction against Delta.

bioRxiv · Jul 1, 2021 · PreprintImmunology

Human AdV-20-42-42, a promising novel adenoviral vector for gene therapy and vaccine product development

M. Z. Ballmann, S. Raus, R. Engelhart, G. L. Kajan, C. van der Zalm, T. Papp, L. John, S. Khan, J. Custers, W. A. M. Bakker, H. M. van der Schaar, N. Arnberg, A. Lemckert, M. Havenga, A. H. Baker

This paper describes the development of a novel adenoviral vector, HAdV-20-42-42, which shows promise for gene therapy and vaccination due to its low seroprevalence and effective transduction capabilities.

bioRxiv · Mar 11, 2021Immunology

Immunogenicity and protective efficacy of one- and two-dose regimens of the Ad26.COV2.S COVID-19 vaccine candidate in adult and aged rhesus macaques

L. Solforosi, H. Kuipers, S. K. Rosendahl Huber, J. E. M. van der Lubbe, L. Dekking, D. N. Czapska-Casey, A. Izquierdo Gil, M. Baert, J. Drijver, J. Vaneman, E. van Huizen, Y. Choi, J. Vreugdenhil, S. Kroos, A. H. de Wilde, , R. C. Zahn

This study evaluates one- and two-dose regimens of the Ad26.COV2.S vaccine in rhesus macaques, showing higher antibody responses with two doses and protection against SARS-CoV-2 in aged animals.

bioRxiv · Nov 17, 2020Immunology

Ad26-vector based COVID-19 vaccine encoding a prefusion stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses

R. Bos, L. Rutten, J. E. M. van der Lubbe, M. J. G. Bakkers, G. Hardenberg, F. Wegmann, D. Zuijdgeest, A. H. de Wilde, A. Koornneef, A. Verwilligen, D. van Manen, T. Kwaks, R. Vogels, T. J. Dalebout, S. K. Myeni, , H. Schuitemaker

This paper evaluates a prefusion-stabilized SARS-CoV-2 Spike protein vaccine candidate, Ad26.COV2.S, showing potent neutralizing and Th1-polarized immune responses in mice.

bioRxiv · Jul 30, 2020Immunology